U.S. Markets close in 26 mins
  • S&P 500

    3,634.04
    -1.37 (-0.04%)
     
  • Dow 30

    29,893.49
    -152.75 (-0.51%)
     
  • Nasdaq

    12,112.76
    +75.98 (+0.63%)
     
  • Russell 2000

    1,848.45
    -5.08 (-0.27%)
     
  • Crude Oil

    45.65
    +0.74 (+1.65%)
     
  • Gold

    1,806.70
    +2.10 (+0.12%)
     
  • Silver

    23.40
    +0.10 (+0.41%)
     
  • EUR/USD

    1.1925
    +0.0028 (+0.2385%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.32
    -0.32 (-1.48%)
     
  • GBP/USD

    1.3390
    +0.0032 (+0.2383%)
     
  • USD/JPY

    104.4270
    -0.0530 (-0.0507%)
     
  • BTC-USD

    18,888.45
    -152.38 (-0.80%)
     
  • CMC Crypto 200

    373.45
    +2.93 (+0.79%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Has DaVita (DVA) Outpaced Other Medical Stocks This Year?

Zacks Equity Research
·2 min read

Investors focused on the Medical space have likely heard of DaVita (DVA), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of DVA and the rest of the Medical group's stocks.

DaVita is one of 896 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. DVA is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for DVA's full-year earnings has moved 9.01% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

According to our latest data, DVA has moved about 1.37% on a year-to-date basis. In comparison, Medical companies have returned an average of -12.78%. As we can see, DaVita is performing better than its sector in the calendar year.

Looking more specifically, DVA belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 17 individual stocks and currently sits at #54 in the Zacks Industry Rank. On average, this group has lost an average of 15.30% so far this year, meaning that DVA is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track DVA. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DaVita Inc. (DVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research